COMP <GO>
ACAD vs JNJ // OPERATING MARGIN
ACADIA Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ACAD 5
— JNJ 7
▲ OPERATING MARGIN LEADER: JNJ
LAST: $20.76 (+2.17%) • MKT CAP: $3.58B
operating-margins
9.80%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
operating-margins
34.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACAD VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACAD | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.70% | 67.90% | +23.80 | ACAD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.90% | 25.50% | -17.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.2x | 18.5x | +12.70 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.94% | 2.97% | -0.03 | JNJ | /fcf-yield <GO> |
| Operating Margin ACTIVE | 9.80% | 34.70% | -24.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 36.50% | 28.50% | +8.00 | ACAD | /net-margins <GO> |
| Revenue Growth (YoY) | 11.90% | 6.00% | +5.90 | ACAD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.26 | 5.59 | +0.67 | ACAD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 62.1 | -16.58 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.5x | 23.0x | -14.50 | ACAD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.58B | $662.49B | -$658.91B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACAD REV | JNJ REV | ACAD GROSS % | JNJ GROSS % | ACAD FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.07B | $94.19B | 91.7% | 67.9% | $105.1M | $19.70B |
| FY 2024 | $957.8M | $88.82B | 91.5% | 69.1% | $157.2M | $19.84B |
| FY 2023 | $726.4M | $85.16B | — | — | $16.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACAD // BETA —
JNJ // BETA 1.08